"CD27 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.
| Descriptor ID |
D053282
|
| MeSH Number(s) |
D12.644.276.374.750.030 D12.776.395.092 D12.776.467.374.750.030 D12.776.543.550.170 D23.529.374.750.030
|
| Concept/Terms |
CD27 Ligand- CD27 Ligand
- Ligand, CD27
- Antigens, CD70
- CD70 Antigens
- Tumor Necrosis Factor Ligand Superfamily Member 7
- CD27L Protein
- CD70 Antigen
- Antigen, CD70
- TNF Superfamily, Member 7
|
Below are MeSH descriptors whose meaning is more general than "CD27 Ligand".
Below are MeSH descriptors whose meaning is more specific than "CD27 Ligand".
This graph shows the total number of publications written about "CD27 Ligand" by people in this website by year, and whether "CD27 Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD27 Ligand" by people in Profiles.
-
PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. J Clin Pathol. 2024 Oct 20; 77(11):761-765.
-
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov. 2024 Jul 01; 14(7):1176-1189.
-
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Arch. 2024 Nov; 485(5):937-941.
-
Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. J Immunol. 2023 10 01; 211(7):1067-1072.
-
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 02 13; 41(2):340-355.e6.
-
CD70 is a potential target biomarker in peripheral T-cell lymphomas. Histopathology. 2022 08; 81(2):272-275.
-
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021 07 29; 138(4):318-330.
-
LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019 Jun; 44:126-137.
-
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014 Dec; 32(6):1246-57.
-
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.